Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · Real-Time Price · USD
4.902
+0.012 (0.24%)
Dec 27, 2024, 11:18 AM EST - Market open
Evoke Pharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 11.34 | 4.74 | 9.84 | 9.14 | 8.07 | 5.66 | Upgrade
|
| Cash & Short-Term Investments | 11.34 | 4.74 | 9.84 | 9.14 | 8.07 | 5.66 | Upgrade
|
| Cash Growth | 90.10% | -51.85% | 7.64% | 13.33% | 42.46% | 6.48% | Upgrade
|
| Receivables | 2.02 | 0.67 | 0.62 | 0.3 | 0.02 | - | Upgrade
|
| Inventory | 0.49 | 0.48 | 0.29 | 0.19 | 0.24 | - | Upgrade
|
| Prepaid Expenses | 0.15 | 0.89 | 0.95 | 0.92 | 0.92 | 0.58 | Upgrade
|
| Other Current Assets | 0.04 | 0.05 | 0.01 | 0.01 | 0.03 | - | Upgrade
|
| Total Current Assets | 14.04 | 6.83 | 11.72 | 10.56 | 9.28 | 6.25 | Upgrade
|
| Property, Plant & Equipment | - | - | 0.13 | 0.01 | 0.14 | 0.14 | Upgrade
|
| Long-Term Deferred Charges | 0.12 | 0.24 | - | - | - | - | Upgrade
|
| Other Long-Term Assets | - | - | - | - | 0.01 | 0.01 | Upgrade
|
| Total Assets | 14.15 | 7.07 | 11.85 | 10.57 | 9.43 | 6.4 | Upgrade
|
| Accounts Payable | 1.9 | 1.6 | 0.87 | 0.87 | 1.27 | 1.03 | Upgrade
|
| Accrued Expenses | 2.71 | 2.98 | 0.59 | 0.52 | 1.02 | 0.84 | Upgrade
|
| Short-Term Debt | - | - | - | - | 0.1 | - | Upgrade
|
| Current Portion of Long-Term Debt | 5 | 5 | - | - | - | - | Upgrade
|
| Current Portion of Leases | - | - | 0.13 | 0.01 | 0.14 | 0.14 | Upgrade
|
| Other Current Liabilities | 0.16 | 0.07 | 0.07 | - | 5 | - | Upgrade
|
| Total Current Liabilities | 9.77 | 9.65 | 1.65 | 1.41 | 7.54 | 2.02 | Upgrade
|
| Long-Term Debt | - | - | 5 | 5 | 5 | - | Upgrade
|
| Other Long-Term Liabilities | - | - | 1.11 | 0.61 | 0.11 | - | Upgrade
|
| Total Liabilities | 9.77 | 9.65 | 7.77 | 7.02 | 12.65 | 2.02 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 131.99 | 120.86 | 119.73 | 110.98 | 95.67 | 90.11 | Upgrade
|
| Retained Earnings | -127.6 | -123.44 | -115.65 | -107.42 | -98.89 | -85.73 | Upgrade
|
| Shareholders' Equity | 4.39 | -2.58 | 4.08 | 3.56 | -3.21 | 4.38 | Upgrade
|
| Total Liabilities & Equity | 14.15 | 7.07 | 11.85 | 10.57 | 9.43 | 6.4 | Upgrade
|
| Total Debt | 5 | 5 | 5.13 | 5.01 | 5.25 | 0.14 | Upgrade
|
| Net Cash (Debt) | 6.34 | -0.26 | 4.71 | 4.13 | 2.82 | 5.53 | Upgrade
|
| Net Cash Growth | 566.25% | - | 14.09% | 46.38% | -48.91% | 3.88% | Upgrade
|
| Net Cash Per Share | 4.30 | -0.94 | 18.00 | 18.49 | 15.95 | 35.69 | Upgrade
|
| Filing Date Shares Outstanding | 2.07 | 0.71 | 0.28 | 0.23 | 0.22 | 0.17 | Upgrade
|
| Total Common Shares Outstanding | 1.48 | 0.28 | 0.28 | 0.23 | 0.18 | 0.17 | Upgrade
|
| Working Capital | 4.27 | -2.82 | 10.07 | 9.15 | 1.75 | 4.23 | Upgrade
|
| Book Value Per Share | 2.97 | -9.26 | 14.66 | 15.68 | -17.39 | 25.82 | Upgrade
|
| Tangible Book Value | 4.39 | -2.58 | 4.08 | 3.56 | -3.21 | 4.38 | Upgrade
|
| Tangible Book Value Per Share | 2.97 | -9.26 | 14.66 | 15.68 | -17.39 | 25.82 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.